

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

## **BUSINESS UPDATE FRAMEWORK AGREEMENT WITH HIGHTIDE THERAPEUTICS, INC. FOR JOINT RESEARCH AND DEVELOPMENT**

The board (the “**Board**”) of directors (the “**Directors**”) of SSY Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Shijiazhuang No. 4 Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of the Company) has entered into a strategic cooperation framework agreement (the “**Framework Agreement**”) with a wholly-owned subsidiary of HighTide Therapeutics, Inc. (a company the shares of which are listed on The Stock Exchange of Hong Kong Limited (stock code: 2511)) (the “**Business Partner**”) , aiming to combine the Group’s extensive experiences in activity screening, formulation development, achievement transformation, quality and cost control, etc., with HighTide Therapeutics, Inc.’s unique advantage in the field of natural products multi-system collaborative innovation, to jointly tackle industry challenges and to provide breakthrough solutions globally in the fields of metabolic chronic diseases, longevity and anti-aging, etc.

### **FRAMEWORK AGREEMENT**

Pursuant to the Framework Agreement and in accordance with its terms and conditions, the Group and HighTide Therapeutics, Inc. (“**both parties**”) will leverage their respective advantages in joint research and development globally in the fields of metabolic chronic diseases, longevity and anti-aging, etc and accomplishment of a full-chain of work including achievement transformation, submission for approval for market launch and conducting market promotion for cooperative projects, which will include establishing a joint research center, researching and developing innovative products, building industry ecosystem, and conducting market promotion and commercialization.

The Framework Agreement merely provides a framework for the strategic cooperation between both parties, and specific cooperation agreement (if any) will be separately entered into by both parties or the entities designated by both parties after negotiation between both parties.

## INFORMATION ABOUT HIGHTIDE THERAPEUTICS, INC.

HighTide Therapeutics, Inc. is a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Stock Exchange of Hong Kong Limited (Stock Code: 2511). HighTide Therapeutics, Inc. is a globally integrated new biopharmaceutical company focusing on areas such as metabolic and digestive system diseases with significant unmet clinical needs.

To the best of the knowledge, information and belief of the Directors having made all reasonable enquiry, HighTide Therapeutics, Inc., the Business Partner and their respective ultimate beneficial owner(s) are third parties independent of and not connected with the Company and its connected persons. The Framework Agreement and the transactions contemplated thereunder do not constitute any notifiable transaction or connected transaction of the Company under Chapter 14 and Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. The Company will issue an announcement regarding the Framework Agreement as and when appropriate in accordance with the Listing Rules.**

By order of the Board

**Chow Hing Yeung**

*Executive Director and Company Secretary*

Hong Kong, 19 December 2024

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.*